Business
Steriwave Expands into ENT Surgery in Spain
Ondine Biomedical Inc. has announced the expansion of its Steriwave nasal photodisinfection technology into ENT surgery centres in Spain, targeting procedures like septoplasty, sinuplasty, and functional endoscopic sinus surgery, which represent a significant growth area with approximately 600,000 annual procedures in the USA, including over 300,000 for Chronic Rhinosinusitis. This non-invasive, five-minute treatment effectively destroys bacteria, viruses, and fungi, including antibiotic-resistant strains, and has demonstrated a 77% reduction in post-operative antibiotic use in prior ENT surgery applications. The company highlights that Steriwave promotes rapid restoration of a healthy nasal microbiome, offering a non-antibiotic approach to reduce infection risk, shorten hospital stays, and deliver cost savings. Disclaimer*
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n22 January 2026\n \nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\n \nSteriwave Expands into ENT Surgery in Spain\n \nOndine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies, is pleased to announce the deployment of its Steriwave® nasal photodisinfection technology into a leading ear, nose and throat (ENT) specialist group operating surgical centres in Madrid and Málaga.\nMany ENT procedures involve operating in, or passing through, the nasal cavity. Sinonasal procedures (septoplasty, sinuplasty and functional endoscopic sinus surgery (FESS) and cytoreductive surgery for cancer) represent an important growth area for Steriwave with about 600,000 procedures performed in the USA annually. Of this number, Chronic Rhinosinusitis (CRS) alone represents over 300,000 procedures annually. CRS is a disease with strong infectious and inflammatory components and is a major health burden.1 Infection risk is further elevated in patients with Chronic Rhinosinusitis (CRS).\nCRS is the second more common chronic disease condition affecting about 12%-15% of adults in western countries1. CRS patients, due to repeated antibiotic and steroid treatments, have nasal microbiomes that are often dominated by multidrug resistant pathogens. Frequent administration of broad-spectrum antibiotics may further deplete the resident microbiome, permitting overgrowth of pathogenic species such as Staph aureus.2 CRS is a common disease linked to a disrupted nasal microbiome, which antibiotics may worsen1. Up to 70% of complex cases with nasal polyps (CRSwNP) involve Staph. aureus colonization3,5,6 and about 30% of CRS patients are colonized with multidrug resistant bacteria like MRSA and Pseudomonas3. These \"superbugs\" can form persistent biofilms, significantly increase post-surgical risk and further disrupt the nasal microbiome4.\nSteriwave has already demonstrated meaningful clinical impact in ENT surgery, as reported by Professor Claire Hopkins, Professor of Rhinology at King's College London and Consultant ENT Surgeon at Guy's & St Thomas' NHS Foundation Trust. In her practice, applying Steriwave prior to sinonasal surgery led to a 77% reduction in post-operative antibiotic use, with prescription rates falling from 22.5% to 5% (P=0.02).7\nSteriwave is a five-minute,...